OncoMatch

OncoMatch/Clinical Trials/NCT06708663

HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid Tumours

Is NCT06708663 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies HX009+IN10018 for biliary tract cancer.

Phase 1/2RecruitingHangzhou Hanx Biopharmaceuticals, Ltd.NCT06708663Data as of May 2026

Treatment: HX009+IN10018Phase IIa study of HX009+ IN10018 in combination with or without standard chemotherapy in patients with advanced solid tumours including biliary tract malignancies and malignant melanoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Cholangiocarcinoma

Melanoma

Biomarker criteria

Excluded: BRAF v600e

Excluded: BRAF v600e

Excluded: FGFR2 fusion

Excluded: IDH1 mutation

Excluded: KRAS mutation

Excluded: NRAS mutation

Excluded: NTRK1 fusion

Excluded: NTRK2 fusion

Excluded: NTRK3 fusion

Excluded: RET fusion

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Cardiac function

No severe cardiovascular disease such as symptomatic congestive heart failure (NYHA Class III or IV), unstable angina, uncontrolled hypertension (systolic blood pressure ≥160 and/or diastolic blood pressure ≥100 mmHg under pharmacological control), cardiac arrhythmia, history of myocardial infarction within 6 months, or history of arterial thromboembolism or pulmonary embolism within 3 months prior to the first administration of the drug

have severe cardiovascular disease such as symptomatic congestive heart failure (New York Heart Association Class III or IV), unstable angina, uncontrolled hypertension (systolic blood pressure ≥160 and/or diastolic blood pressure ≥100 mmHg under pharmacological control), cardiac arrhythmia, history of myocardial infarction within 6 months, or history of arterial thromboembolism or pulmonary embolism within 3 months prior to the first administration of the drug

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify